Juliette Servante1, Gill Swallow2, Jim G Thornton3, Bethan Myers4, Sandhya Munireddy4, A Kinga Malinowski5, Maha Othman6,7, Wentao Li8, Keelin O'Donoghue9, Kate F Walker3. 1. Department of Obstetrics and Gynaecology, Nottingham University Hospitals NHS Trust, Nottingham, UK. Juliette.servante@nottingham.ac.uk. 2. Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK. 3. Division of Child Health, Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Nottingham, UK. 4. Department of Haematology, University Hospitals of Leicester, Leicester, UK. 5. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 6. Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University Kingston, Kingston, Ontario, Canada. 7. School of Baccalaureate Nursing, St Lawrence College, Kingston, Ontario, Canada. 8. Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia. 9. The Irish Centre for Maternal and Child Health, University College Cork, Cork University Maternity Hospital, Cork, Ireland.
Abstract
BACKGROUND: As pregnancy is a physiological prothrombotic state, pregnant women may be at increased risk of developing coagulopathic and/or thromboembolic complications associated with COVID-19. METHODS: Two biomedical databases were searched between September 2019 and June 2020 for case reports and series of pregnant women with a diagnosis of COVID-19 based either on a positive swab or high clinical suspicion where no swab had been performed. Additional registry cases known to the authors were included. Steps were taken to minimise duplicate patients. Information on coagulopathy based on abnormal coagulation test results or clinical evidence of disseminated intravascular coagulation (DIC), and on arterial or venous thrombosis, were extracted using a standard form. If available, detailed laboratory results and information on maternal outcomes were analysed. RESULTS: One thousand sixty-three women met the inclusion criteria, of which three (0.28, 95% CI 0.0 to 0.6) had arterial and/or venous thrombosis, seven (0.66, 95% CI 0.17 to 1.1) had DIC, and a further three (0.28, 95% CI 0.0 to 0.6) had coagulopathy without meeting the definition of DIC. Five hundred and thirty-seven women (56%) had been reported as having given birth and 426 (40%) as having an ongoing pregnancy. There were 17 (1.6, 95% CI 0.85 to 2.3) maternal deaths in which DIC was reported as a factor in two. CONCLUSIONS: Our data suggests that coagulopathy and thromboembolism are both increased in pregnancies affected by COVID-19. Detection of the former may be useful in the identification of women at risk of deterioration.
BACKGROUND: As pregnancy is a physiological prothrombotic state, pregnant women may be at increased risk of developing coagulopathic and/or thromboembolic complications associated with COVID-19. METHODS: Two biomedical databases were searched between September 2019 and June 2020 for case reports and series of pregnant women with a diagnosis of COVID-19 based either on a positive swab or high clinical suspicion where no swab had been performed. Additional registry cases known to the authors were included. Steps were taken to minimise duplicate patients. Information on coagulopathy based on abnormal coagulation test results or clinical evidence of disseminated intravascular coagulation (DIC), and on arterial or venous thrombosis, were extracted using a standard form. If available, detailed laboratory results and information on maternal outcomes were analysed. RESULTS: One thousand sixty-three women met the inclusion criteria, of which three (0.28, 95% CI 0.0 to 0.6) had arterial and/or venous thrombosis, seven (0.66, 95% CI 0.17 to 1.1) had DIC, and a further three (0.28, 95% CI 0.0 to 0.6) had coagulopathy without meeting the definition of DIC. Five hundred and thirty-seven women (56%) had been reported as having given birth and 426 (40%) as having an ongoing pregnancy. There were 17 (1.6, 95% CI 0.85 to 2.3) maternal deaths in which DIC was reported as a factor in two. CONCLUSIONS: Our data suggests that coagulopathy and thromboembolism are both increased in pregnancies affected by COVID-19. Detection of the former may be useful in the identification of women at risk of deterioration.
Authors: F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman Journal: Thromb Res Date: 2020-04-10 Impact factor: 3.944
Authors: Xiaofang Guo; Nihan Semerci; Viviana De Assis; Umit A Kayisli; Frederick Schatz; Thora S Steffensen; Ozlem Guzeloglu-Kayisli; Charles J Lockwood Journal: Front Immunol Date: 2022-04-07 Impact factor: 8.786
Authors: Marcin Januszewski; Laura Ziuzia-Januszewska; Alicja A Jakimiuk; Waldemar Wierzba; Anna Gluszko; Joanna Zytynska-Daniluk; Artur J Jakimiuk Journal: Int J Environ Res Public Health Date: 2021-11-16 Impact factor: 3.390
Authors: Jae Hoon Lee; Jae Yen Song; Kyong Wook Yi; Jin Ju Kim; Kyu Ri Hwang; Jung-Ho Shin; Ji Young Lee; Hee Dong Chae Journal: Obstet Gynecol Sci Date: 2022-01-26
Authors: Sara Cruz Melguizo; María Luisa de la Cruz Conty; Paola Carmona Payán; Alejandra Abascal-Saiz; Pilar Pintando Recarte; Laura González Rodríguez; Celia Cuenca Marín; Alicia Martínez Varea; Ana Belén Oreja Cuesta; Pilar Prats Rodríguez; Irene Fernández Buhigas; María Victoria Rodríguez Gallego; Ana María Fernández Alonso; Rocío López Pérez; José Román Broullón Molanes; María Begoña Encinas Pardilla; Mercedes Ramírez Gómez; María Joaquina Gimeno Gimeno; Antonio Sánchez Muñoz; Oscar Martínez-Pérez Journal: Viruses Date: 2021-05-07 Impact factor: 5.048
Authors: Christina Crossette-Thambiah; Phillip Nicolson; Indika Rajakaruna; Alexander Langridge; Zara Sayar; Maria R Perelta; Sarah Essex; Roderick Oakes; Philip Mounter; Sarah Lewis; Tina Dutt; Ian Scott; Nini Aung; Susie Shapiro; Mike Laffan; Deepa R J Arachchillage Journal: Br J Haematol Date: 2021-06-24 Impact factor: 8.615